Quality of Life Analysis of TORCH, a Randomized Trial Testing First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer
Massimo Di Maïo(University of Siena), Cesare Gridelli(Azienda Ospedaliera S.Giuseppe Moscati), Ferdinando Riccardi(Ospedale Antonio Cardarelli), Ronald Feld(University Health Network), Saverio Cinieri(Ospedale A. Perrino), Floriana Morgillo(University of Campania "Luigi Vanvitelli"), Raffaella Felletti(Apple (Israel)), Natasha B. Leighl(Princess Margaret Cancer Centre), Vittorio Gebbia(Università degli Studi di Enna Kore), Ciro Gallo(University of Campania "Luigi Vanvitelli"), Giovenzio Genestreti(Apple (Israel)), Mario Spatafora(Ospedale Vincenzo Cervello), Paolo Maione(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Salvatore Siena(University of Milan), Antônio Rossi(Università Campus Bio-Medico), Gianfranco Mancuso, Morena Fasano, Roberto Bianco(Federico II University Hospital), Vittorio Fregoni(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Alessandro Morabito(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Adolfo Favaretto(Istituto Oncologico Veneto), Fortunato Ciardiello(University of Campania "Luigi Vanvitelli"), Ming‐Sound Tsao(Kumamoto University), Francesco Perrone(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Alberto Ravaioli(Florence (Netherlands)), Yasmin Alam(Ottawa Hospital), Simona Signoriello(University of Campania "Luigi Vanvitelli"), Rafal Wierzbicki(King Faisal Specialist Hospital & Research Centre), Charles Butts(Apple (Israel))
Cited by 26
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k